There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Cabaletta Bio Inc. (CABA) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $4.68. The Cabaletta Bio Inc. has recorded 11,540 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Cabaletta Bio to Present at the 5th Annual Evercore ISI HealthCONx Conference.
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $4.68 and fluctuated between $5.1600 as its day high and $4.4800 as its day low. The current market capitalization of Cabaletta Bio Inc. is $138.15M. A total of 1.53 million shares were traded on the day, compared to an average of 1.27M shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, CABA has seen 7 BUY and 0 SELL insider trades, representing the acquisition of 346,000 and the disposition of 0 shares. Over the last 12 months, there were 8 BUYs and 0 SELLs from insiders. Insiders purchased 396,000 shares during that period but sold 0.
In the most recent transaction, Nichtberger Steven bought 8,127 shares of CABA for 1.25 per share on Oct 19. After the transaction, the President & CEO now owns 986,483 company shares. In a previous transaction on Oct 18, Simon Mark bought 7,000 shares at 0.98 per share. CABA shares that Director owns now total 7,000.
Among the insiders who bought shares, Simon Mark acquired of 118,000 shares on Oct 18 at a per-share price of $0.98. This resulted in the Director holding 136,144 shares of CABA after the transaction. In another insider transaction, Bollard Catherine bought 1,000 shares at $0.99 per share on Oct 18. Company shares held by the Director now total 1,000.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for CABA in the last 3 months, the mean price target is $7.83 with high estimates of $12.00 and low estimates of $3.00. In terms of 52-week highs and lows, CABA has a high of $13.24 and a low of $0.59.
As of this writing, CABA has an earnings estimate of -$0.48 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.43 per share and a lower estimate of -$0.56. The company reported an EPS of -$0.45 in the last quarter, which was 25.00% higher than expectations of -$0.6.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 7 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CABA is Overweight with a score of 4.67. A total of 6 analysts rated the stock as Buy while 0 rated it as Overweight while 1 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.